Hereditary Spastic Paraplegia
34
15
16
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.9%
1 terminated out of 34 trials
92.9%
+6.4% vs benchmark
3%
1 trials in Phase 3/4
8%
1 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (34)
12-Week Strength and Functional Exercise Program for Hereditary Spastic Paraplegia Trial (HSPMOVE)
Neuromodulation to Enhance Motor Function in HSP
D-Cycloserine for Serine Palmitoyltransferase Inhibition
STOP-HSP.Net: a Registry for Hereditary Spastic Paraplegia as an Integration Tool for Future Therapeutic Strategies
Phenotype, Genotype and Biomarkers 2
Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)
Registry and Natural History Study for Early Onset Hereditary Spastic Paraplegia
Spastic Paraplegia - Centers of Excellence Research Network
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Robot-assisted Walking Treatment in Hereditary Spastic Paraplegia (HSP)
Safety and Efficacy of AAV9/AP4B1 (BFB-101) For Patients With AP4B1-related Hereditary Spastic Paraplegia Type 47 (SPG47)
A Prospective Cohort Study of Surgical Treatment for Foot Deformities in HSP
Natural History Study of Patients with HPDL Mutations
Single and Multiple Ascending Dose Study of MTR-601 in Healthy Individuals
A Prospective Cohort Study of ITB Treatment for HSP
Flexibility, Resistance, Aerobic, Movement Execution Training in Adults With Hereditary Spastic Paraplegia
Calcium Folinate Treatment of Spastic Paraplegia 56
Assessment of the Psychophysical State During Rehabilitation Treatment With Lokomat